BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vermeulen K, Vandamme M, Bormans G, Cleeren F. Design and Challenges of Radiopharmaceuticals. Semin Nucl Med 2019;49:339-56. [PMID: 31470930 DOI: 10.1053/j.semnuclmed.2019.07.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Chen D, Augusto RDS, Liang J, Qin Z, Liu J, Liu Z. Production Review of Accelerator-Based Medical Isotopes. Molecules 2022;27:5294. [PMID: 36014532 DOI: 10.3390/molecules27165294] [Reference Citation Analysis]
2 Ahenkorah S, Murce E, Cawthorne C, Ketchemen JP, Deroose CM, Cardinaels T, Seimbille Y, Fonge H, Gsell W, Bormans G, Ooms M, Cleeren F. 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals. Theranostics 2022;12:5971-85. [PMID: 35966589 DOI: 10.7150/thno.75336] [Reference Citation Analysis]
3 Damasceno A, Pijeira MSO, Ricci-junior E, Alencar LMR, İlem-özdemir D, Santos-oliveira R. Exploiting the Extemporaneousness of Radiopharmaceuticals: Radiolabeling Stability under Diverse Conditions. Journal of Pharmaceutical and Biomedical Analysis 2022. [DOI: 10.1016/j.jpba.2022.115024] [Reference Citation Analysis]
4 Venet M, Friedberg MK, Mertens L, Baranger J, Jalal Z, Tlili G, Villemain O. Nuclear Imaging in Pediatric Cardiology: Principles and Applications. Front Pediatr 2022;10:909994. [PMID: 35874576 DOI: 10.3389/fped.2022.909994] [Reference Citation Analysis]
5 English KK, Knox S, Graves SA, Kiess AP. Basics of Physics and Radiobiology for Radiopharmaceutical Therapies. Pract Radiat Oncol 2022;12:289-93. [PMID: 35717042 DOI: 10.1016/j.prro.2022.04.004] [Reference Citation Analysis]
6 Chen H, Jiang Z, Cheng X, Zheng W, Sun Y, Yu Z, Yang T, Zhang L, Yan J, Liu Y, Ji X, Wu Z. [18F]BIBD-239: 18F-Labeled ER176, a Positron Emission Tomography Tracer Specific for the Translocator Protein. Mol Pharm 2022. [PMID: 35671264 DOI: 10.1021/acs.molpharmaceut.2c00157] [Reference Citation Analysis]
7 Zheng W, Cheng X, Chen H, Jiang Z, Sun Y, Yu Z, Yang T, Zhang L, Liu Y, Ji X, Wu Z. Novel 18F-Labeled PET Tracers Specific to Aromatase: Design, Synthesis, and Biological Evaluation. Mol Pharm 2022. [PMID: 35621695 DOI: 10.1021/acs.molpharmaceut.2c00176] [Reference Citation Analysis]
8 Parrilha GL, dos Santos RG, Beraldo H. Applications of radiocomplexes with thiosemicarbazones and bis(thiosemicarbazones) in diagnostic and therapeutic nuclear medicine. Coordination Chemistry Reviews 2022;458:214418. [DOI: 10.1016/j.ccr.2022.214418] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
9 Cui X, Liu Y, Wang C, Wen Z, Li Y, Tang H, Diwu J, Yang Y, Cui M, Liu Z. China’s radiopharmaceuticals on expressway: 2014–2021. Radiochimica Acta 2022;0. [DOI: 10.1515/ract-2021-1137] [Reference Citation Analysis]
10 Jiang Z, Cheng X, Chen H, Zheng W, Sun Y, Yu Z, Yang T, Zhang L, Fan D, Yang Z, Liu Y, Ai L, Wu Z. [18F]BIBD-181: A Novel Positron Emission Tomography Tracer Specific for Synaptic Vesicle Glycoprotein 2A. ACS Med Chem Lett 2022;13:720-6. [PMID: 35450380 DOI: 10.1021/acsmedchemlett.2c00062] [Reference Citation Analysis]
11 Te Beek ET, Burggraaf J, Teunissen JJM, Vriens D. Clinical Pharmacology of Radiotheranostics in Oncology. Clin Pharmacol Ther 2022. [PMID: 35373336 DOI: 10.1002/cpt.2598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Yuan MK, Chang SC, Yuan MC, Foo NP, Chan SH, Wang SY, Lin CL, Hsu CY, Kao CH. Pediatric Nuclear Medicine Examinations and Subsequent Risk of Neoplasm: A Nationwide Population-Based Cohort Study. Front Med (Lausanne) 2021;8:764849. [PMID: 34988089 DOI: 10.3389/fmed.2021.764849] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Le Fur M, Fougère O, Lepareur N, Rousseaux O, Tripier R, Beyler M. Tuning the lipophilic nature of pyclen-based 90Y3+ radiopharmaceuticals for β-radiotherapy. Metallomics 2021;13:mfab070. [PMID: 34850060 DOI: 10.1093/mtomcs/mfab070] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhou X, Dong L, Shen L. Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals. Molecules 2021;26:6997. [PMID: 34834087 DOI: 10.3390/molecules26226997] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Griffith DM, Li H, Werrett MV, Andrews PC, Sun H. Medicinal chemistry and biomedical applications of bismuth-based compounds and nanoparticles. Chem Soc Rev 2021;50:12037-69. [PMID: 34533144 DOI: 10.1039/d0cs00031k] [Cited by in Crossref: 1] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ataeinia B, Heidari P. Artificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development:: In Silico Smart Molecular Design. PET Clin 2021:S1556-8598(21)00047-X. [PMID: 34364818 DOI: 10.1016/j.cpet.2021.06.008] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
17 Ayşe U, Aziz G, Doğangün Y. High-Efficiency Cationic Labeling Algorithm of Macroaggregated Albumin with 68Gallium. Nucl Med Mol Imaging 2021;55:79-85. [PMID: 33968274 DOI: 10.1007/s13139-021-00687-6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
18 Ahenkorah S, Cassells I, Deroose CM, Cardinaels T, Burgoyne AR, Bormans G, Ooms M, Cleeren F. Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside. Pharmaceutics 2021;13:599. [PMID: 33919391 DOI: 10.3390/pharmaceutics13050599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kleynhans J, Kruger HG, Cloete T, Zeevaart JR, Ebenhan T. In Silico Modelling in the Development of Novel Radiolabelled Peptide Probes. CMC 2020;27:7048-63. [DOI: 10.2174/0929867327666200504082256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Hassan H, Othman MF, Zakaria ZA, Saad FFA, Abdul Razak HR. Analytical GC-FID Method for the Determination of Organic Solvents in Radiopharmaceuticals. Curr Radiopharm 2021;14:131-44. [PMID: 33115398 DOI: 10.2174/1874471013999201027215704] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Tosato M, Asti M, Dalla Tiezza M, Orian L, Häussinger D, Vogel R, Köster U, Jensen M, Andrighetto A, Pastore P, Marco VD. Highly Stable Silver(I) Complexes with Cyclen-Based Ligands Bearing Sulfide Arms: A Step Toward Silver-111 Labeled Radiopharmaceuticals. Inorg Chem 2020;59:10907-19. [PMID: 32658468 DOI: 10.1021/acs.inorgchem.0c01405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
22 Datta P, Ray S. Nanoparticulate formulations of radiopharmaceuticals: Strategy to improve targeting and biodistribution properties. J Labelled Comp Radiopharm 2020. [PMID: 32220029 DOI: 10.1002/jlcr.3839] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
23 Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, Deroose CM, Cleeren F. Automated GMP compliant production of [18F]AlF-NOTA-octreotide. EJNMMI Radiopharm Chem 2020;5:4. [PMID: 31997090 DOI: 10.1186/s41181-019-0084-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
24 Sathekge MM, Bouchelouche K. Letter from the Editors. Semin Nucl Med 2019;49:337-8. [PMID: 31470929 DOI: 10.1053/j.semnuclmed.2019.06.014] [Reference Citation Analysis]